Understanding the Natural History of Sickle Cell Trait
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
This study is trying to learn more about Sickle Cell Trait by following people with it for two years to see how it affects their blood and if it leads to any health issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Alliance for Sickle Cell Centers Academic / other |
| Locations | 10 sites (Birmingham, Alabama and 9 other locations) |
| Trial ID | NCT06071377 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a longitudinal cohort of individuals with Sickle Cell Trait (SCT) to better understand the hematologic characteristics associated with carrying HbS. It will assess variations in HbS levels and explore potential clinical complications related to SCT. Participants will provide biological specimens and undergo testing to confirm their SCT status over a two-year period. The study seeks to gather comprehensive data to enhance knowledge about SCT.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 who know or suspect they have Sickle Cell Trait and are willing to participate in the study.
Not a fit: Patients with known end-stage renal disease, sickle cell disease, or those who do not have Sickle Cell Trait will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the health implications of Sickle Cell Trait, potentially leading to improved management and care for affected individuals.
How similar studies have performed: While this study focuses on a specific aspect of Sickle Cell Trait, similar observational studies have provided valuable insights into related conditions, suggesting potential for meaningful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Are willing to voluntarily participate and sign the study consent 2. Know/suspect they have SCT and are willing to get tested to confirm/learn about their SCT status 3. Adults ages 18 and older Exclusion Criteria: 1. Unwilling to sign consent 2. Known end-stage renal disease or dialysis 3. Known SCD (including sickle cell-beta thalassemia) 4. People who do not have SCT
Where this trial is running
Birmingham, Alabama and 9 other locations
- University of Alabama — Birmingham, Alabama, United States (Recruiting)
- Loma Linda University Health Care — Loma Linda, California, United States (Recruiting)
- Nemours Children's Hospital — Wilmington, Delaware, United States (Recruiting)
- Indiana University — Indianapolis, Indiana, United States (Recruiting)
- Functional Fluidics — Detroit, Michigan, United States (Recruiting)
- University of North Carolina — Chapel Hill, North Carolina, United States (Recruiting)
- Duke University — Durham, North Carolina, United States (Recruiting)
- East Carolina University — Greenville, North Carolina, United States (Recruiting)
- Nationwide Children's Hospital — Columbus, Ohio, United States (Recruiting)
- UT Health Houston — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Julie Kanter, MD — National Alliance for Sickle Cell Centers
- Study coordinator: Julie Kanter, MD
- Email: jkanter@sicklecellcenters.org
- Phone: (202) 596-1548
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.